Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Transdermal Spray-on Patch Treatment for ADHD, Alzheimers, Parkinsons, Athletes' Foot, Epilepsy, Migraine...
Formuli United Kingdom flag United Kingdom
Abstract ID:
This is an invisible spray-on patch which cannot be felt. It is a considerable improvement over existing transdermal patch treatment for ADHD and Alzheimer's where fidgeting, agitated, aggressive or confused patients may take off the transdermal pat...
Contact Russ Pendleton
Participants
You
Email me a copy of this message
MECHANISM OF ACTION
All product molecules have already been approved by regulatory authorities.

A spray-on patch therapy exists that can allow dosing of patients through an invisible and unfelt spray-on patch. Cost of goods are low – a simple metered dose aerosol with simple excipients. Transdermal patches exist for ADHD and Alzheimers which allow for 505b2 route through regulatory approval in the US, and similar phase III waiver in Europe. Estimated costs from Proof of Concept through to NDA submission are around USD3M. Further QoL/Adherence study work would support higher pricing of the launched product.

Global IP is strong, and production facilities can be arranged. Anticipated time through to commercialisation is 3 years.

This is a 505b2/phase III waiver product - Phase III is probably most descriptive as only one more BE study is required.

Proof of Concept exists for ADHD. This now requires scale up for clinical supplies, a bioequivalence study then Dossier preparation.

Type of Business Relationship Sought
Funding, joint-venture, out-licensing
FEATURED
Last Updated Aug 2016
Technology Type THERAPEUTIC
Phase of Development CLINICAL TRIALS
CORPORATION